Pasithea Therapeutics Corp. (KTTAW) EPS (Basic) (2021 - 2026)

Pasithea Therapeutics has disclosed EPS (Basic) across 6 years of filings, most recently posting -$0.16 for Q2 2026.

• In Q2 2026, EPS (Basic) rose 75.06% year-over-year to -$0.16; the TTM figure through Jun 2026 stood at -$0.66 (up 72.19% YoY), while the FY2025 annual figure was -$2.91, up 77.1% from the prior year.
• EPS (Basic) came in at -$0.16 for Q2 2026 at Pasithea Therapeutics, down from -$0.12 in the prior quarter.
• In the past five years, EPS (Basic) ranged from a high of -$0.12 in Q1 2026 to a low of -$6.76 in Q4 2022.
• Average EPS (Basic) over 5 years is -$2.47, with a median of -$2.79 recorded in 2023.
• Year-over-year, EPS (Basic) slumped 658.06% in 2022 and soared 92.68% in 2026.
• Over 5 years, EPS (Basic) stood at -$6.76 in 2022, then jumped by 38.33% to -$4.17 in 2023, then surged by 30.45% to -$2.9 in 2024, then jumped by 50.4% to -$1.44 in 2025, then jumped by 88.58% to -$0.16 in 2026.
• Per Business Quant data, the three most recent EPS (Basic) figures were -$0.16 in Q2 2026, -$0.12 in Q1 2026, and -$1.44 in Q4 2025.